Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis
This study is for people with rheumatoid arthritis (RA) whose current medicines aren't fully controlling their condition. Doctors usually start with standard drugs like methotrexate. If these don't work well, stronger 'biologic' medicines are considered. This trial explores a new treatment plan: starting with a type of biologic called a TNF inhibitor for 12 weeks to quickly reduce inflammation, then switching to another biologic called abatacept for the next 36 weeks. Researchers want to see if this two-step approach is more effective and easier to tolerate compared to just continuing with a TNF inhibitor. They believe this might help some RA patients feel better and achieve lasting remission.
במבט חטוף
על מה המחקר הזה?
If you have rheumatoid arthritis (RA) that isn't fully controlled by your current medications, this study might be of interest. Typically, doctors first prescribe standard drugs like methotrexate or leflunomide. If these don't work sufficiently, the next step often involves adding stronger medicines, known as 'biologics' or 'targeted synthetic DMARDs', which work in different ways to calm the immune system and reduce inflammation.
Currently, many doctors tend to start with a type of biologic called a TNF inhibitor. However, there's another biologic called abatacept, which is known for having fewer side effects, although some doctors believe it might take a bit longer to start working. This study is designed to see if we can get the best of both worlds. The idea is to begin with a TNF inhibitor for 12 weeks to quickly bring down the inflammation, and then switch to abatacept for the next 36 weeks. The researchers hope this strategy could lead to better control of RA and fewer side effects in the long run, especially for people who have specific markers in their blood (called ACPA positive).
The study compares this new two-step approach against simply continuing with a TNF inhibitor. It's important to understand that this is a research study to find out if this specific sequence of treatments is more effective and safer. It's a way for doctors to explore better treatment options for people living with RA, aiming to help more patients achieve a state where their disease is well-controlled.
נקודות עיקריות
- This study explores a new two-step treatment approach for RA.
- It's for people whose RA isn't fully controlled by standard medicines.
- Compares starting with a TNF inhibitor then switching to abatacept vs. staying on a TNF inhibitor.
- Aim is to find a more effective and tolerable treatment path.
- Requires ACPA positive RA and no prior use of advanced biologics.
- Participation involves regular clinic visits and monitoring for 48 weeks.
מי עשוי להיות זכאי?
To join this study, you need to be an adult, aged 18 or older, and have rheumatoid arthritis that has been confirmed by doctors. Your RA must also be considered 'ACPA positive', which is a type of antibody found in your blood that’s common in RA. You must currently be taking methotrexate or leflunomide for at least three months, but these medications aren't fully controlling your RA, meaning you still have some ongoing inflammation.
It's important that you haven't taken other advanced biologics or targeted synthetic medicines for RA before. The study also requires you to have a clear reason why your doctor would typically recommend starting a TNF inhibitor. There are also reasons why you might not be able to join, such as if you have certain heart conditions, untreated tuberculosis, or if you can't commit to all the study visits for 48 weeks. Pregnant or breastfeeding women, or women who could become pregnant and aren't using effective birth control, also cannot participate.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- האם אתה בן 18 או יותר?
- Have you been diagnosed with rheumatoid arthritis by a doctor?
- Are your blood tests 'ACPA positive'?
- Are you currently taking methotrexate or leflunomide for at least 3 months, but your RA is not fully controlled?
- Have you never taken other advanced biologic or targeted synthetic RA medications before?
- Are you able to attend all study visits over 48 weeks (almost a year)?
מה כרוך בהשתתפות?
If you decide to take part, the study will last for 48 weeks. You'll be randomly assigned to one of two groups: either you'll start with a TNF inhibitor medicine for 12 weeks and then switch to abatacept for the next 36 weeks, or you'll continue with a TNF inhibitor. You will have regular appointments at the clinic for assessments, which will include blood tests and checks of your RA symptoms and how you're feeling. These visits are important for the doctors to monitor your progress and ensure your safety throughout the study.
סיכונים ותועלות פוטנציאליים
מיקומים (17)
- Centre Hospitalier Universitaire de Montpellierמיקוד מאומתמונפלייה, צרפת· גיוס
- CHU Bordeaux groupe Pellegrinמיקוד מאומתבורדו, צרפת· גיוס
- CHU de Brest La Cavale Blancheמיקוד מאומתברסט, צרפת· גיוס
- Centre Hospitalier de Cahorsמיקוד מאומתCahors, France· עדיין לא מגייסים
- CHD Vendéeמיקוד מאומתLa Roche-sur-Yon, France· גיוס
- CH du Mansמיקוד מאומתLe Mans, France· גיוס
- CHU de Nantesמיקוד מאומתננט, צרפת· גיוס
- CHU de Niceמיקוד מאומתניס, צרפת· גיוס
- CHU de Nîmes Carémeauמיקוד מאומתNîmes, France· עדיין לא מגייסים
- CHR Orléans Nouvel hôpital d'Orléansמיקוד מאומתOrléans, France· גיוס
- APHP Bicêtreמיקוד מאומתפריז, צרפת· עדיין לא מגייסים
- APHP Cochinמיקוד מאומתפריז, צרפת· גיוס
שאלות נפוצות
What is ACPA positive?
ACPA positive means you have certain antibodies in your blood that are often found in people with rheumatoid arthritis.
What are TNF inhibitors and abatacept?
These are types of 'biologic' medicines that target specific parts of your immune system to reduce inflammation in rheumatoid arthritis.
כמה זמן נמשך המחקר?
The study will last for 48 weeks, which is about 11 months.
Will I have to stop my current RA medicine?
You will likely continue your current methotrexate or leflunomide, and the study medicines will be added on top of that.
Is this a new medicine?
The medicines themselves are not new, but this study is looking at a new way of using them in sequence.
כיצד לגלות עוד
Jacques MOREL, MD-PhD
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.